Photo of Laura M. Heiser, Ph.D.

Laura M. Heiser Ph.D.

  • (503) 346-4617
    • Associate Professor of Biomedical Engineering School of Medicine
    • OHSU Center for Spatial Systems Biomedicine

Dr. Heiser's research is focused on identifying pathways and aberrations associated with therapeutic response and resistance in cancer. In her studies, she uses an integrative systems biology approach to understand cancer as a complex system. Dr. Heiser is also an active member of the DREAM Consortium, which is a community-based effort to rigorously assess and advance algorithms in computational biology.

Education

  • B.A., University of California, Berkeley California 1998
  • Ph.D., University of Pittsburgh 2004

Publications

  • "LSD1 activates a lethal prostate cancer gene network independently of its demethylase function." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 115, No. 18, 01.05.2018, p. E4179-E4188.
  • "Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes." Cell Systems  In: , 01.01.2018.
  • "MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance." Nature Communications  In: , Vol. 8, No. 1, 1728, 01.12.2017.
  • "Pathway-enriched gene signature associated with 53BP1 response to PARP inhibition in triple-negative breast cancer." Molecular Cancer Therapeutics  In: , Vol. 16, No. 12, 01.12.2017, p. 2892-2901.
  • "Combating subclonal evolution of resistant cancer phenotypes." Nature Communications  In: , Vol. 8, No. 1, 1231, 01.12.2017.
  • "Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics." Scientific data  In: , Vol. 4, 170166, 07.11.2017.
  • "Correction : Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2+ breast cancer (PLoS ONE (2015) 10:7 (e0133219) DOI: 10.1371/journal.pone.0133219)." PLoS One  In: , Vol. 12, No. 10, e0186551, 01.10.2017.
  • "HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2 breast cancer." Clinical Cancer Research  In: , Vol. 23, No. 17, 01.09.2017, p. 5123-5134.
  • "Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes." Genome Medicine  In: , Vol. 9, No. 1, 40, 26.04.2017.
  • "Erratum to : "Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer", [Breast Cancer Research, 19, (2017) (17)] DOI: 10.1186/s13058-017-0809-6." Breast Cancer Research  In: , Vol. 19, No. 1, 17, 09.02.2017.
  • "Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling." Cell Systems  In: , Vol. 4, No. 1, 25.01.2017, p. 73-83.e10.
  • "The Library of Integrated Network-Based Cellular Signatures NIH Program : System-Level Cataloging of Human Cells Response to Perturbations." Cell Systems  In: , 01.01.2017.
  • "Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer." Oncotarget  In: , Vol. 8, No. 67, 01.01.2017, p. 111084-111095.
  • "FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 113, No. 43, 25.10.2016, p. E6600-E6609.
  • "PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder." Scientific Reports  In: , Vol. 6, 31750, 30.08.2016.
  • "Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer." Breast Cancer Research  In: , Vol. 18, No. 1, 70, 01.07.2016.
  • "Inferring causal molecular networks : Empirical assessment through a community-based effort." Nature Methods  In: , Vol. 13, No. 4, 30.03.2016, p. 310-318.
  • "Tumor-derived cell lines as molecular models of cancer pharmacogenomics." Molecular Cancer Research  In: , Vol. 14, No. 1, 01.01.2016, p. 3-13.
  • "Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor." Oncotarget  In: , Vol. 7, No. 26, 2016, p. 40690.
  • "Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy." Clinical Cancer Research  In: , Vol. 21, No. 17, 01.09.2015, p. 3995-4003.
  • "Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2+ breast cancer." PLoS One  In: , Vol. 10, No. 7, e0133219, 16.07.2015.
  • "Erratum to Modeling precision treatment of breast cancer [Genome Biology, 14, (2013), R110]." Genome Biology  In: , Vol. 16, No. 1, 95, 12.05.2015.
  • "Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma." Oncotarget  In: , Vol. 6, No. 42, 2015, p. 44675-44687.
  • "A network-based model of oncogenic collaboration for prediction of drug sensitivity." Frontiers in Genetics  In: , Vol. 6, No. DEC, 00341, 2015.
  • "A community effort to assess and improve drug sensitivity prediction algorithms." Nature Biotechnology  In: , Vol. 32, No. 12, 01.12.2014, p. 1202-1212.
  • "A community computational challenge to predict the activity of pairs of compounds." Nature Biotechnology  In: , Vol. 32, No. 12, 01.12.2014, p. 1213-1222.
  • "Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase." Breast Cancer Research  In: , Vol. 16, No. 5, 430, 11.09.2014.
  • "Metrics other than potency reveal systematic variation in responses to cancer drugs." Nature Chemical Biology  In: , Vol. 9, No. 11, 11.2013, p. 708-714.
  • "A robust prognostic signature for hormone-positive node-negative breast cancer." Genome Medicine  In: , Vol. 5, No. 10, 92, 11.10.2013.
  • "Modeling precision treatment of breast cancer." Genome Biology  In: , Vol. 14, No. 10, 2013.

Additional information

Edit profile